Sirolimus Pharmacokinetics Variability Points to the Relevance of Therapeutic Drug Monitoring in Pediatric Oncology.

Fiche publication

Date publication

mars 2021

Journal

Pharmaceutics

Auteurs

Membres identifiés du Cancéropôle Est :
Pr ENTZ-WERLE Natacha , Pr LESSINGER Jean-Marc , Dr JANNIER Sarah

Tous les auteurs :
Sabo AN, Jannier S, Becker G, Lessinger JM, Entz-Werlé N, Kemmel V

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/33808416

Résumé

Sirolimus is widely used in transplantation, where its therapeutic drug monitoring (TDM) is well established. Evidence of a crucial role for sirolimus in the PI3K/AkT/mTor pathway has stimulated interest in its involvement in neoplasia, either as monotherapy or in combination with other antineoplastic agents. However, in cancer, there is no consensus on sirolimus TDM. In the RAPIRI phase I trial, the combination sirolimus + irinotecan was evaluated as a new treatment for refractory pediatric cancers. Blood sampling at first sirolimus intake (D1) and at steady state (D8), followed by LC/MS analysis, was used to develop a population pharmacokinetic model (Monolix software). A mono-compartmental model with first-order absorption and elimination best fit the data. The only covariate retained for the final model was "body surface area" (D1 and D8). The model also demonstrated that 1.5 mg/m would be the recommended sirolimus dose for further studies and that steady-state TDM is necessary to adjust the dosing regimen in atypical profiles (36.4% of the population). No correlation was found between sirolimus trough concentrations and efficacy and/or observed toxicities. The study reveals the relevance of sirolimus TDM in pediatric oncology as it is needed in organ transplantation.